Cantor Fitzgerald analyst Sarah James downgraded Health Catalyst (HCAT) to Neutral from Overweight with a price target of $4, down from $9. The firm cites the company’s worsening revenue outlook amid multi-year headwinds for the downgrade. Cantor believes the macro environment is too difficult to support growth at Health Catalyst.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT: